KR880014373A - Diagnostic Analysis of Immune Responses Using Chimeric Antigens - Google Patents

Abstract

No content

Description

Diagnostic Analysis of Immune Responses Using Chimeric Antigens

Since this is an open matter, no full text was included.

Claims (24)

A) a solid support; b) an antibody that binds to the solid support; c) the first and second reactions with an antibody bound to the first antigen site but not with an antibody that recognizes the fifth antigen site. An immunological response diagnostic instrument for analyzing the presence of an antibody against a specific antigen, consisting of a chimeric antigen having an antigenic site. The apparatus of claim 1, wherein the second antigenic site represents a pathogenic microorganism, protein, virus or cell. The apparatus of claim 2 representing a protein or protein fragment in which the first antigenic site does not recognize the binding site in the animal body fluids. The apparatus of claim 3, wherein the second antigenic site is an antigen derived from a protein associated with a cancer, genetic abnormality, bacterial, fungal, viral or parasitic disease. A method of producing a chimeric HIV-antigen, comprising fusion of a portion of the galK gene to an HIV gene fragment, thereby introducing the fused gene fragment into the organism and culturing the organism to the extent that the chimeric HIV-antigen is expressed. The method of claim 5, wherein the chimeric HIV-antigen accumulates to a high level and is stable when expressed in Escherichia coli. The method of claim 5, wherein the chimeric antigen is encoded by the gene coding sequence for galK fused to the p24gag coding sequence of HIV. The method of claim 5, wherein the chimeric antigen is encoded by the gene coding sequence for galK fused to the p55gag coding sequence of HIV. The method of claim 5, wherein the chimeric antigen is encoded by a gene coding sequence for galK fused to a reverse transcriptase-internal nuclease (RTdue) coding sequence of HIV. The method of claim 5, wherein the chimeric antigen is encoded by the gene coding sequence for galK fused to the p41env coding sequence of HIV. The method of claim 5, wherein the chimeric antigen is encoded by the gene coding sequence for galK fused to the coding sequence of the p120env amino terminal (C) half of HIV. The method of claim 5, wherein the chimeric antigen consists of a gene coding sequence for galK fused to the coding sequence of the p120env carboxy terminal (C) half of HIV. A method for detecting an anti-HIV antibody in a sample consisting of contacting the sample with a galK-HIV chimeric antigen bound to a solid support such that only the sample comprising HIV-specific immunoglobulins binds to the HIV-chimeric antigen. The method of claim 13, wherein the chimeric antigen is attached to the solid support by the galK site such that all HIV epitopes present on the molecule can be identified by the sample. A vector consisting of a promoter and a sequence of galK genes and coding sequences for antigens that do not cross react with galK adjacent to it. The galK translational fusion vector of claim 15 known as galK-p24gag. The galK translational fusion vector of claim 15 known as galK-p55gag. The galK translational fusion vector of claim 15, also known as galK-RT endo. The galK translational fusion vector of claim 15 known as galK-p41env. The galK translational fusion vector of claim 15 known as galK-p120env (N). The galK translational fusion vector of claim 15 known as galK-p120env (C). Escherichia coli transformed with the galK translational fusion vector of claim 16, 17, 18, 19, 20 or 21. A chimeric HIV antigen consisting of an HIV antigen site and a second antigen site that does not cross-react with antibodies that recognize the HIV antigen site. Chimeric HIV antigens produced by any of the methods of claims 5-12. ※ Note: The disclosure is based on the initial application.